NASDAQ:VCNX Vaccinex (VCNX) Stock Price, News & Analysis → Elon’s New Device is About to Shock the World (From InvestorPlace) (Ad) Free VCNX Stock Alerts $6.86 -0.34 (-4.73%) (As of 06/14/2024 ET) Add Compare Share Share Today's Range$6.56▼$7.7750-Day Range$4.76▼$7.4952-Week Range$4.43▼$97.04Volume25,979 shsAverage Volume35,877 shsMarket Capitalization$10.83 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Vaccinex alerts: Email Address Vaccinex MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy1.32% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.29Based on 3 Articles This WeekInsider TradingAcquiring Shares$6,071 Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.06 out of 5 starsMedical Sector568th out of 914 stocksPharmaceutical Preparations Industry267th out of 429 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Vaccinex.Read more about Vaccinex's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.32% of the float of Vaccinex has been sold short.Short Interest Ratio / Days to CoverVaccinex has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Vaccinex has recently decreased by 23.33%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldVaccinex does not currently pay a dividend.Dividend GrowthVaccinex does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VCNX. Previous Next 4.0 News and Social Media Coverage News SentimentVaccinex has a news sentiment score of 1.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.91 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Vaccinex this week, compared to 0 articles on an average week.Search Interest2 people have searched for VCNX on MarketBeat in the last 30 days. MarketBeat Follows2 people have added Vaccinex to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vaccinex insiders have bought more of their company's stock than they have sold. Specifically, they have bought $6,071.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders51.50% of the stock of Vaccinex is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions50.11% of the stock of Vaccinex is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Vaccinex's insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Vaccinex is -0.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vaccinex is -0.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Vaccinex's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Freeport SocietyA Silent Invasion of AmericaThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern border is a travesty, but the 'invasion' I've found will have 10 times greater effects on our economy, and ultimately our way of life.Go here to see why. About Vaccinex Stock (NASDAQ:VCNX)Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 study for treatment of Alzheimer's disease and has completed phase 2 study for treatment of Huntington's disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer, Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 study with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab completed phase 2 study for melanoma, and trastuzumab and DC vaccine in phase 2 study for breast cancer. The company has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. It has collaborations with Merck Sharp & Dohme; Ares Trading S.A.; The Children's Hospital of Philadelphia; Emory University; Huntington Study Group; H. Lee Moffitt Cancer Center and Research Institute, Inc; Catalent Pharma Solutions, LLC; Surface Oncology, Inc.; and Pharmaceutical and Biotech Co. The company was incorporated in 2001 and is headquartered in Rochester, New York.Read More VCNX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VCNX Stock News HeadlinesJune 15 at 7:56 AM | americanbankingnews.comVaccinex, Inc. (NASDAQ:VCNX) Short Interest Down 23.3% in MayJune 6, 2024 | globenewswire.comVaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer's DiseaseMay 16, 2024 | finanznachrichten.deVaccinex, Inc.: Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 16, 2024 | investorplace.comVCNX Stock Earnings: Vaccinex Reported Results for Q1 2024May 15, 2024 | globenewswire.comVaccinex Reports First Quarter 2024 Financial Results and Provides Corporate UpdateApril 14, 2024 | investing.comVaccinex faces Nasdaq compliance challengeApril 2, 2024 | investorplace.comVCNX Stock Earnings: Vaccinex Reported Results for Q4 2023April 2, 2024 | globenewswire.comVaccinex Reports 2023 Financial Results and Provides Corporate UpdateMarch 27, 2024 | globenewswire.comVaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq RulesMarch 6, 2024 | investing.comVaccinex CFO Scott Royer to retire, Jill Sanchez steps inMarch 2, 2024 | morningstar.comVaccinex Inc VCNXFebruary 21, 2024 | finanznachrichten.deVaccinex, Inc.: Vaccinex Announces Multiple New Agreements for Access to ActivMAb Antigen Virus TechnologyFebruary 21, 2024 | markets.businessinsider.comVaccinex Enters Antibody Discovery Agreements Incorporating ActivMAb Drug Discovery PlatformFebruary 21, 2024 | finance.yahoo.comVaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus TechnologyFebruary 21, 2024 | globenewswire.comVaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus TechnologyFebruary 15, 2024 | markets.businessinsider.comVaccinex Announces 1-For-14 Reverse Stock SplitFebruary 15, 2024 | msn.comWhy Vaccinex (VCNX) Stock Is Trading LowerFebruary 15, 2024 | globenewswire.comVaccinex, Inc. Announces Reverse Stock SplitFebruary 12, 2024 | finance.yahoo.comSteven Cohen's Point72 Asset Management Acquires New Stake in Vaccinex IncFebruary 8, 2024 | msn.comVaccinex Inc Secures $3.7M in Private Placement DealFebruary 7, 2024 | msn.comWhy Vaccinex (VCNX) Stock Is Popping OffFebruary 7, 2024 | markets.businessinsider.comVaccinex Announces Pricing of $3.7 Million PIPE FinancingDecember 4, 2023 | finance.yahoo.comNasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing RuleNovember 13, 2023 | finance.yahoo.comVaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateOctober 31, 2023 | finance.yahoo.comVaccinex Reports Clinical Benefit in Interim Analyses from two Phase 2 Studies of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual MeetingSee More Headlines Receive VCNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vaccinex and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today6/16/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:VCNX CUSIPN/A CIK1205922 Webwww.vaccinex.com Phone(585) 271-2700Fax585-271-2765Employees37Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($82.8030) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-20,250,000.00 Net MarginsN/A Pretax Margin-15,472.58% Return on Equity-2,667.31% Return on Assets-461.17% Debt Debt-to-Equity RatioN/A Current Ratio1.52 Quick Ratio1.52 Sales & Book Value Annual Sales$570,000.00 Price / Sales19.00 Cash FlowN/A Price / Cash FlowN/A Book Value($2.59) per share Price / Book-2.65Miscellaneous Outstanding Shares1,580,000Free Float768,000Market Cap$10.83 million OptionableNo Data Beta0.86 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Maurice Zauderer Ph.D. (Age 77)Co-Founder, CEO, President & Director Comp: $411.7kDr. Elizabeth E. Evans Ph.D. (Age 51)COO and Senior VP of Discovery & Translational Medicine Comp: $291.57kDr. Ernest S. Smith Ph.D. (Age 52)Senior VP of Research & Chief Scientific Officer Comp: $297.25kMs. Jill Sanchez CPA (Age 52)Chief Financial Officer Dr. John E. Leonard Ph.D. (Age 77)Senior Vice President of Development Key CompetitorsCumberland PharmaceuticalsNASDAQ:CPIXNabriva TherapeuticsNASDAQ:NBRVDURECTNASDAQ:DRRXOcuphire PharmaNASDAQ:OCUPCASI PharmaceuticalsNASDAQ:CASIView All CompetitorsInsidersAlbert FriedbergBought 957 shares on 5/29/2024Total: $4,737.15 ($4.95/share)Albert FriedbergBought 282 shares on 4/19/2024Total: $1,333.86 ($4.73/share)Strydonck Gerald E. VanSold 224 sharesTotal: $2,257.92 ($10.08/share)Albert FriedbergBought 214,285 shares on 10/3/2023Total: $3.00 M ($14.00/share)Maurice ZaudererBought 357 shares on 10/3/2023Total: $4,648.14 ($13.02/share)View All Insider Transactions VCNX Stock Analysis - Frequently Asked Questions How have VCNX shares performed in 2024? Vaccinex's stock was trading at $9.3072 on January 1st, 2024. Since then, VCNX shares have decreased by 26.3% and is now trading at $6.8550. View the best growth stocks for 2024 here. Are investors shorting Vaccinex? Vaccinex saw a decrease in short interest in the month of May. As of May 31st, there was short interest totaling 9,200 shares, a decrease of 23.3% from the May 15th total of 12,000 shares. Based on an average daily volume of 17,400 shares, the days-to-cover ratio is currently 0.5 days. Approximately 1.3% of the company's stock are short sold. View Vaccinex's Short Interest. When is Vaccinex's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our VCNX earnings forecast. How were Vaccinex's earnings last quarter? Vaccinex, Inc. (NASDAQ:VCNX) issued its quarterly earnings data on Wednesday, May, 15th. The company reported ($2.94) earnings per share (EPS) for the quarter. The business had revenue of $0.10 million for the quarter. When did Vaccinex's stock split? Vaccinex's stock reverse split on the morning of Tuesday, February 20th 2024. The 1-14 reverse split was announced on Tuesday, February 20th 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 20th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Vaccinex own? Based on aggregate information from My MarketBeat watchlists, some companies that other Vaccinex investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Aldeyra Therapeutics (ALDX), Sorrento Therapeutics (SRNE), Cerecor (CERC), Exelixis (EXEL), Pfizer (PFE), AVEO Pharmaceuticals (AVEO), Heat Biologics (HTBX) and SCYNEXIS (SCYX). When did Vaccinex IPO? Vaccinex (VCNX) raised $45 million in an IPO on Thursday, August 9th 2018. The company issued 3,300,000 shares at a price of $12.00-$15.00 per share. Oppenheimer and BTIG acted as the underwriters for the IPO and Ladenburg Thalmann was co-manager. How do I buy shares of Vaccinex? Shares of VCNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VCNX) was last updated on 6/16/2024 by MarketBeat.com Staff From Our PartnersBUY ALERT: Tiny tech play partners with US governmentThe Federal Reserve is rolling out a powerful new financial technology across the entire U.S. banking system. ...Stansberry Research | SponsoredBill Clinton Backing Biden Replacement???Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaccinex, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaccinex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.